Vestibular Disorders Therapeutics
1. Aqneursa patent expiration
Treatment: Use of levacetylleucine for treatment of neurological manifestations of niemann-pick disease type-c (npc); Treatment of neurological manifestations of niemann-pick disease type-c (npc) for a duration ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400067 | INTRABIO | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Apr, 2037
(11 years from now) | |
| US12433863 | INTRABIO | Pharmaceutical Compositions And Uses Directed To Lysosomal Storage Disorders |
Apr, 2037
(11 years from now) | |
| US12433862 | INTRABIO | Pharmaceutical Compositions And Uses Directed To Lysosomal Storage Disorders |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2029 |
| Orphan Drug Exclusivity(ODE-498) | Sep 24, 2031 |
Drugs and Companies using LEVACETYLLEUCINE ingredient
NCE-1 date: 24 September, 2028
Market Authorisation Date: 24 September, 2024
Dosage: FOR SUSPENSION
More Information on Dosage
AQNEURSA family patents
